The global Actemra drug market is mainly driven by the growing prevalence of rheumatoid arthritis (RA) across the world. Actemra or tocilizumab is a drug used for treating moderate to severe active RA in adult patients. As an interleukin-6 receptor antagonist, Actemra works by blocking the action of interleukin-6, a protein that plays a key role in inflammation associated with RA. The... https://www.zupyak.com/p/4494381/t/actemra-drug-market-is-anticipated-to-witness-high-growth-owing-to-rising-prevalence-of-autoimmune-and-inflammatory-diseases